A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib

BACKGROUND: Selumetinib is a potent, selective, orally available, and non-ATP competitive small molecule inhibitor of mitogen-activated protein kinase kinase 1/2 (MEK1/2) that has demonstrated single agent activity in a number of solid tumor including recurrent low-grade serous ovarian carcinoma (LG...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Gynecol Oncol Res Pract
Hoofdauteurs: Takekuma, Munetaka, Wong, Kwong K., Coleman, Robert L.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BioMed Central 2016
Onderwerpen:
Case Report
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4880811/
https://ncbi.nlm.nih.gov/pubmed/27231576
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40661-016-0026-5
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items